AIMS: Little is known regarding acute heart failure (AHF) clinical characteristics and its hospital outcome in Latin America. This study sought to assess the prevalence of, and identify differences among, in-hospital outcomes in patients hospitalized for AHF who were stratified by clinical phenotype at a hospital in Latin America. METHODS AND RESULTS: This is a retrospective cohort study of patients with AHF who were hospitalized in the coronary care unit of a Latin American teaching hospital from January 2006 to December 2018. Cox regression analysis was used to identify predictors of mortality. Of 21 042 patients admitted, 7759 (36.6%) had AHF. Their median age was 62 years, and 35% were women. De novo heart failure was seen in 39.4% of patients. Most common was AHF-associated acute coronary syndromes (ACS-HF) in 43.0%, decompensated heart failure (DHF) in 33.7%, hypertensive heart failure (HT-HF) in 11.8%, and cardiogenic shock (CS) in 5.2%. Pulmonary oedema (PO) (3.3%) and right heart failure (RHF) (3.0%) were least frequent. Coronary artery disease was the most frequent aetiology in 56.5% of patients, valvular heart disease in 22.4%, and cardiomyopathies in 12.3%. Other less frequent aetiology included adult congenital heart disease (2.5%), lung diseases (2.1%), acute aortic syndromes (1.4%), pericardial diseases (0.8%), and intracardiac tumours (0.3%). Aetiology could not be established in 1.6% of patients. Before admission, patients with worsening chronic heart failure and reduced ejection fraction were treated with renin-angiotensin system blockers (60.4%), beta-blockers (42.5%), or spironolactone (34.4%). The percentages of patients given in-hospital management with intravenous diuretics, vasodilators, inotropes, and vasopressors were 81.2%, 33.4%, 18.9%, and 20.4%, respectively. The overall in-hospital mortality was 17.9% (71.3%, 43.9%, 23.8%, 14.9%, 13.6%, and 10.1% for CS, PO, RHF, DHF, ACS-HF, and HT-HF, respectively; P < 0.0001). Multivariate analysis revealed that PO (hazard ratio [HR] 2.68, 95% confidence interval [CI] 1.73-4.14, P < 0.0001) and CS (HR 3.37, 95% CI 2.12-5.35, P < 0.0001) were independent predictors of in-hospital mortality. Use of intravenous diuretics was linked to reduction of in-hospital mortality (HR 0.70, 95% CI 0.59-0.59, P < 0.0001). By contrast, increased in-hospital mortality was associated with the use of intravenous inotrope or vasopressor (HR 1.49, 95% CI 1.27-1.76 and HR 2.91, 95% CI 2.41-3.51, P < 0.0001, respectively). CONCLUSIONS: Real-world evidence from a university hospital in Latin America shows that the high mortality among patients with AHF may depend, among other factors, on patients' AHF clinical phenotypes. The clinical characteristics and aetiologies of AHF appear to differ between these data from Mexico and those from European and US registries.
AIMS: Little is known regarding acute heart failure (AHF) clinical characteristics and its hospital outcome in Latin America. This study sought to assess the prevalence of, and identify differences among, in-hospital outcomes in patients hospitalized for AHF who were stratified by clinical phenotype at a hospital in Latin America. METHODS AND RESULTS: This is a retrospective cohort study of patients with AHF who were hospitalized in the coronary care unit of a Latin American teaching hospital from January 2006 to December 2018. Cox regression analysis was used to identify predictors of mortality. Of 21 042 patients admitted, 7759 (36.6%) had AHF. Their median age was 62 years, and 35% were women. De novo heart failure was seen in 39.4% of patients. Most common was AHF-associated acute coronary syndromes (ACS-HF) in 43.0%, decompensated heart failure (DHF) in 33.7%, hypertensive heart failure (HT-HF) in 11.8%, and cardiogenic shock (CS) in 5.2%. Pulmonary oedema (PO) (3.3%) and right heart failure (RHF) (3.0%) were least frequent. Coronary artery disease was the most frequent aetiology in 56.5% of patients, valvular heart disease in 22.4%, and cardiomyopathies in 12.3%. Other less frequent aetiology included adult congenital heart disease (2.5%), lung diseases (2.1%), acute aortic syndromes (1.4%), pericardial diseases (0.8%), and intracardiac tumours (0.3%). Aetiology could not be established in 1.6% of patients. Before admission, patients with worsening chronic heart failure and reduced ejection fraction were treated with renin-angiotensin system blockers (60.4%), beta-blockers (42.5%), or spironolactone (34.4%). The percentages of patients given in-hospital management with intravenous diuretics, vasodilators, inotropes, and vasopressors were 81.2%, 33.4%, 18.9%, and 20.4%, respectively. The overall in-hospital mortality was 17.9% (71.3%, 43.9%, 23.8%, 14.9%, 13.6%, and 10.1% for CS, PO, RHF, DHF, ACS-HF, and HT-HF, respectively; P < 0.0001). Multivariate analysis revealed that PO (hazard ratio [HR] 2.68, 95% confidence interval [CI] 1.73-4.14, P < 0.0001) and CS (HR 3.37, 95% CI 2.12-5.35, P < 0.0001) were independent predictors of in-hospital mortality. Use of intravenous diuretics was linked to reduction of in-hospital mortality (HR 0.70, 95% CI 0.59-0.59, P < 0.0001). By contrast, increased in-hospital mortality was associated with the use of intravenous inotrope or vasopressor (HR 1.49, 95% CI 1.27-1.76 and HR 2.91, 95% CI 2.41-3.51, P < 0.0001, respectively). CONCLUSIONS: Real-world evidence from a university hospital in Latin America shows that the high mortality among patients with AHF may depend, among other factors, on patients' AHF clinical phenotypes. The clinical characteristics and aetiologies of AHF appear to differ between these data from Mexico and those from European and US registries.
Authors: Veli-Pekka Harjola; Johan Lassus; Alessandro Sionis; Lars Køber; Tuukka Tarvasmäki; Jindrich Spinar; John Parissis; Marek Banaszewski; Jose Silva-Cardoso; Valentina Carubelli; Salvatore Di Somma; Heli Tolppanen; Uwe Zeymer; Holger Thiele; Markku S Nieminen; Alexandre Mebazaa Journal: Eur J Heart Fail Date: 2015-03-28 Impact factor: 15.534
Authors: Ovidiu Chioncel; Alexandre Mebazaa; Veli-Pekka Harjola; Andrew J Coats; Massimo Francesco Piepoli; Maria G Crespo-Leiro; Cecile Laroche; Petar M Seferovic; Stefan D Anker; Roberto Ferrari; Frank Ruschitzka; Silvia Lopez-Fernandez; Daniela Miani; Gerasimos Filippatos; Aldo P Maggioni Journal: Eur J Heart Fail Date: 2017-04-30 Impact factor: 15.534
Authors: Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi Journal: Eur Heart J Date: 2006-09-25 Impact factor: 29.983
Authors: John E A Blair; Faiez Zannad; Marvin A Konstam; Thomas Cook; Brian Traver; John C Burnett; Liliana Grinfeld; Holly Krasa; Aldo P Maggioni; Cesare Orlandi; Karl Swedberg; James E Udelson; Christopher Zimmer; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2008-11-11 Impact factor: 24.094
Authors: Sean van Diepen; Jeffrey A Bakal; Meng Lin; Padma Kaul; Finlay A McAlister; Justin A Ezekowitz Journal: J Am Heart Assoc Date: 2015-02-27 Impact factor: 5.501
Authors: Héctor González-Pacheco; Amada Álvarez-Sangabriel; Carlos Martínez-Sánchez; José L Briseño-Cruz; Alfredo Altamirano-Castillo; Salvador Mendoza-García; Daniel Manzur-Sandoval; Luis M Amezcua-Guerra; Julio Sandoval; Rafael Bojalil; Diego Araiza-Garaygordobil; Daniel Sierra-Lara; Carlos A Guiza-Sánchez; Rodrigo Gopar-Nieto; Camelia Cruz-Rodríguez; José J Valdivia-Nuño; Brandon Salas-Teles; Alexandra Arias-Mendoza Journal: ESC Heart Fail Date: 2020-11-11
Authors: Héctor González-Pacheco; Amada Álvarez-Sangabriel; Carlos Martínez-Sánchez; José L Briseño-Cruz; Alfredo Altamirano-Castillo; Salvador Mendoza-García; Daniel Manzur-Sandoval; Luis M Amezcua-Guerra; Julio Sandoval; Rafael Bojalil; Diego Araiza-Garaygordobil; Daniel Sierra-Lara; Carlos A Guiza-Sánchez; Rodrigo Gopar-Nieto; Camelia Cruz-Rodríguez; José J Valdivia-Nuño; Brandon Salas-Teles; Alexandra Arias-Mendoza Journal: ESC Heart Fail Date: 2020-11-11